ZYNE · Zynerba Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $86.0K | $7.3K | $0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $21.10M | $21.42M | $35.65M | $20.38M | $27.25M | $22.81M |
| SG&A | $14.15M | $15.35M | $16.41M | $13.94M | $13.24M | $10.02M |
| Total Operating Expenses | $35.25M | $36.77M | $52.06M | $34.32M | $40.48M | $32.82M |
| D&A | $219.3K | $247.1K | $207.0K | $133.9K | $99.6K | $94.2K |
| Operating Income | ($35.25M) | ($36.77M) | ($52.06M) | ($34.32M) | ($40.40M) | ($32.82M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | $0 | - |
| Net Income | ($35.04M) | ($37.31M) | ($51.34M) | ($32.94M) | ($39.91M) | ($32.01M) |
| EPS - Basic | ($0.82) | ($1.90) | - | - | - | - |
| EPS - Diluted | ($0.82) | ($1.90) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.64M | $67.81M | $59.16M | $70.06M | $59.76M | $62.51M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.94M | $1.80M | $2.52M | $4.74M | $4.46M | $3.36M |
| Current Assets | $54.78M | $80.22M | $73.37M | $87.06M | $66.96M | $68.23M |
| Total Assets | $55.52M | $81.17M | $74.06M | $87.76M | $67.33M | $69.05M |
| Current Liabilities | $9.17M | $9.90M | $13.91M | $12.06M | $9.73M | $7.44M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $9.29M | $10.26M | $13.91M | $12.17M | $9.73M | $6.97M |
| Stockholders' Equity | $46.23M | $70.91M | $60.14M | $75.60M | $57.60M | $60.95M |
| Retained Earnings | ($274.52M) | ($239.48M) | ($202.17M) | ($150.84M) | ($117.89M) | ($77.98M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($23.03M) | ($33.46M) | ($41.31M) | ($34.82M) | ($32.40M) | ($20.44M) |
| Investing Cash Flow | ($154.1K) | ($47.6K) | ($445.3K) | ($129.4K) | ($286.7K) | ($109.6K) |
| Financing Cash Flow | $6.01M | $42.16M | $30.85M | $45.25M | $29.94M | $10.00M |
| CapEx | $154.1K | $47.6K | $445.3K | $129.4K | $286.7K | $115.4K |
| Free Cash Flow | ($23.18M) | ($33.51M) | ($41.76M) | ($34.95M) | ($32.68M) | ($20.55M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | -39906.8% | -557211.4% | - |
| EBITDA margin | - | - | - | -39751.1% | -555838.0% | - |
| Net margin | - | - | - | -38306.5% | -550499.0% | - |
| Free cash flow margin | - | - | - | -40636.5% | -450813.9% | - |
| FCF / Net income | 0.66 | 0.90 | 0.81 | 1.06 | 0.82 | 0.64 |
| R&D / Revenue | - | - | - | 23702.4% | 375793.7% | - |
| SG&A / Revenue | - | - | - | 16204.4% | 182604.0% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -63.1% | -46.0% | -69.3% | -37.5% | -59.3% | -46.4% |
| Return on equity | -75.8% | -52.6% | -85.4% | -43.6% | -69.3% | -52.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 5.97 | 8.10 | 5.27 | 7.22 | 6.88 | 9.17 |
| Quick ratio | 5.97 | 8.10 | 5.27 | 7.22 | 6.88 | 9.17 |
| Cash ratio | 5.52 | 6.85 | 4.25 | 5.81 | 6.14 | 8.40 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.20 | 1.14 | 1.23 | 1.16 | 1.17 | 1.13 |
| Liabilities / Assets | 0.17 | 0.13 | 0.19 | 0.14 | 0.14 | 0.10 |
| Efficiency | ||||||
| Asset turnover | - | - | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | 1086.2% | - | -100.0% |
| Revenue CAGR (3y) | - | - | - | 128.1% | -80.3% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 4.1% | 29.4% | -51.7% | 15.0% | -23.1% | -41.4% |
| Net income growth (YoY) | 6.1% | 27.3% | -55.8% | 17.5% | -24.7% | -36.9% |
| EPS growth (YoY) | 56.8% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 30.8% | 19.8% | -19.5% | -6.9% | -59.0% | -0.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -34.8% | 17.9% | -20.4% | 31.2% | -5.5% | 106.0% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Zynerba Pharmaceuticals against the 5 most active filers in the same SIC group.